Pfizer/BioNTech COVID-19 vaccine shows 90.7% efficacy in trial in children

By Michael Erman NEW YORK (Reuters) -The Pfizer/BioNTech COVID-19 vaccine showed 90.7% efficacy against the coronavirus in a clinical trial of children 5 to 11 years old, the U.S. drugmaker said on Friday. Sixteen children in the trial who had received a placebo got COVID-19, compared with 3 who were vaccinated, Pfizer said in briefing documents submitted to the U.S. Food and Drug Administration. Because more than twice as many children in the 2,268-participant trial were given the vaccine than placebo, that equates to better than 90% efficacy. Pfizer’s clinical trial in those 5 to 11 years old was not